John Houston
Fortune : 9 M $ au 31/05/2026
Fortune : 9 M $ au 31/05/2026
John G. Houston occupe le poste de président, chef de la direction et directeur chez Arvinas, Inc. et président, chef de la direction et directeur chez Arvinas Operations, Inc. (une filiale d'Arvinas, Inc.). Il est également membre du conseil d'administration de NextCure, Inc. et de Cybrexa, Inc. et d'Oerth Bio LLC. John G. Houston a précédemment occupé le poste de vice-président principal chargé de la découverte de spécialités chez Bristol Myers Squibb Co. et celui de chef de l'unité de découverte principale chez GlaxoSmithKline Research & Development Ltd. Il a obtenu un doctorat de l'université de Glasgow et un doctorat de l'université Heriot-Watt.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARVINAS, INC. 1,54 % | 31/03/2026 | 992 689 ( 1,54 % ) | 9 M $ | 31/05/2026 |
NEXTCURE, INC. -.--% | 22/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ARVINAS, INC. | Directeur/Membre du Conseil | 12/02/2026 |
| NEXTCURE, INC. | Directeur/Membre du Conseil | 10/09/2020 |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Directeur Général | 21/09/2017 |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Develops molecule DNA repair inhibitors that directly target the tumor microenvironment | Directeur/Membre du Conseil | 03/09/2019 |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Develops biotechnology products | Directeur/Membre du Conseil | 01/06/2019 |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Provides support services for biomedical research and biotechnology to advance and support research and technology | Directeur/Membre du Conseil | 01/12/2015 |
Bioct Innovation Commons | Directeur/Membre du Conseil | 01/12/2015 |
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/08/2016 |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Functions as a commercial physical research company | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Health Technology |
University of Glasgow
University of Glasgow Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Heriot-Watt University
Heriot-Watt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Connecticut United for Research Excellence, Inc.
Connecticut United for Research Excellence, Inc. Miscellaneous Commercial ServicesCommercial Services Provides support services for biomedical research and biotechnology to advance and support research and technology | Commercial Services |
GlaxoSmithKline Research & Development Ltd.
GlaxoSmithKline Research & Development Ltd. Miscellaneous Commercial ServicesCommercial Services Functions as a commercial physical research company | Commercial Services |
Arvinas, Inc.
Arvinas, Inc. BiotechnologyHealth Technology Engages in discovery, development and commercialization of therapies to degrade disease-causing proteins | Health Technology |
NextCure, Inc.
NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Develops molecule DNA repair inhibitors that directly target the tumor microenvironment | Health Technology |
Oerth Bio LLC
Oerth Bio LLC BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Bioct Innovation Commons | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national